You are here

Daiichi Sankyo

ESMO: Daiichi dazzles in lung cancer to dial up hopes for next ADC

ESMO: Daiichi dazzles in lung cancer to dial up hopes for next ADC

Fierce Biotech

small cell lung cancer

Flag link:

Seagen loses arbitration case to Daiichi Sankyo over cancer drug technology

Seagen loses arbitration case to Daiichi Sankyo over cancer drug technology

BioPharma Dive

Flag link:

FDA approves AstraZeneca, Daiichi drug in breast cancer first

FDA approves AstraZeneca, Daiichi drug in breast cancer first

BioPharma Dive

HER2-low breast cancer

Flag link:

AstraZeneca wins two recommendations, one priority review

AstraZeneca wins two recommendations, one priority review

Morningstar

Flag link:

Daiichi Sankyo willfully infringed Seagen patent in creating Enhertu, court rules

Daiichi Sankyo willfully infringed Seagen patent in creating Enhertu, court rules

Fierce Pharma

Flag link:

EHA: Survival data sets Daiichi Sankyo’s quizartinib back on track

EHA: Survival data sets Daiichi Sankyo’s quizartinib back on track

Pharmaforum

clinical trials

acute myeloid leukemia

Flag link:

ASCO22: Enhertu aces key HER2-low test in breast cancer

ASCO22: Enhertu aces key HER2-low test in breast cancer

Pharmaforum

HER2-low breast cancer

Flag link:

Former AstraZeneca exec committed insider trading on landmark 2019 Enhertu deal, SEC alleges

Former AstraZeneca exec committed insider trading on landmark 2019 Enhertu deal, SEC alleges

Endpoints

insider trading

Flag link:

The 12 Top Biotech Companies Hiring Now

The 12 Top Biotech Companies Hiring Now

BioSpace

Moderna Therapeutics

Waters Corporation

Gilead Sciences

Emergent BioSolutions

Flag link:

FDA Approves AstraZeneca, Daiichi Sankyo’s ENHERTU in Breast Cancer

FDA Approves AstraZeneca, Daiichi Sankyo’s ENHERTU in Breast Cancer

Contract Pharma

HER2+ breast cancer

Flag link:

FDA starts speedy review of Enhertu in lung cancer

FDA starts speedy review of Enhertu in lung cancer

Pharmaforum

non-small cell lung cancer

Flag link:

Seagen scores $41.8M in Enhertu patent case against Daiichi Sankyo

Seagen scores $41.8M in Enhertu patent case against Daiichi Sankyo

Fierce Pharma

Flag link:

Big day for AZ, Daiichi as Enhertu aces HER2-low breast cancer trial

Big day for AZ, Daiichi as Enhertu aces HER2-low breast cancer trial

Pharmaforum

clinical trials

HER2-low breast cancer

Flag link:

Daiichi makes play for share of Japan’s COVID booster market

Daiichi makes play for share of Japan’s COVID booster market

Pharmaforum

Flag link:

Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development

Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development

Endpoints

Flag link:

Biopharma developments over the Christmas period

Biopharma developments over the Christmas period

EP Vantage

Alnylam Pharmaceuticals

Bio-Thera Solutions

BridgeBio Pharma

Madrigal Pharmaceuticals

Sutro BioPharma

Tasly Pharmaceutical Group

Flag link:

FDA gives Daiichi Sankyo’s HER3 drug a breakthrough tag

FDA gives Daiichi Sankyo’s HER3 drug a breakthrough tag

Pharmaforum

antibody-drug conjugate

patritumab deruxtecan

Flag link:

AZ, Daiichi take aim at Gilead in triple-negative breast cancer

AZ, Daiichi take aim at Gilead in triple-negative breast cancer

Pharmaforum

Gilead Sciences

triple negative breast cancer

Flag link:

Daiichi could be rewarded for persisting with Vanflyta

Daiichi could be rewarded for persisting with Vanflyta

EP Vantage

Flag link:

Daiichi jettisons ADC after flunking early solid tumor test

Daiichi jettisons ADC after flunking early solid tumor test

Fierce Biotech

antibody-drug conjugate

Flag link:

Pages